[CAS NO. 1043854-13-2] J14
PRODUCTS SPECIFICATIONS [1043854-13-2]
DESCRIPTION [1043854-13-2]
Overview
| MDL | MFCD19814303 |
|---|---|
| Molecular Weight | 517.04 |
| Molecular Formula | C28H25ClN4O2S |
| SMILES | O=C(O)C1=CC=C(CSC2=NC(C3=CC=CC=C3)=CC(N4CCN(C5=CC=CC=C5Cl)CC4)=N2)C=C1 |
Summary
IC50 & Target
IC50: 8.1 μM (Sulfiredoxin); ROS [1]
In Vitro
J14 (0-100 μM; 0-96 hours; A549 cells) treatment inhibits the growth of A549 cells in a concentration- and a time- dependent manner, and its half inhibitory concentration for the growth of A549 cells was 15.7 μM
[1]
.
J14 (20 μM; 48-72 hours; A549 cells) treatment causes not only the release of cytochrome c into the cytosol, but also the activation of caspase-3 and caspase-9. J14 induces oxidative damage to mitochondria, resulting in caspase-mediated apoptosis
[1]
.
J14 treatment significantly increases the accumulation of sulfinic peroxiredoxins and intracellular ROS. Excess accumulation of intracellular ROS causes oxidative damage, leading to cell death. J14 significantly induces cell death in A549 cells in a time-dependent manner, resulting in approximately 40% cell death in 96 hours
[1]
.
J14 induces oxidative mitochondrial damage and apoptosis
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | A549 cells |
| Concentration: | 0-100 μM |
| Incubation Time: | 0 hour, 24 hours, 48 hours, 72 hours, 96 hours |
| Result: | Inhibited the growth of A549 cells in a concentration- and a time- dependent manner. |
Western Blot Analysis [1]
| Cell Line: | A549 cells |
| Concentration: | 20 μM |
| Incubation Time: | 48 hours, 72 hours |
| Result: | Caused not only the release of cytochrome c into the cytosol, but also the activation of caspase-3 and caspase-9. |
In Vivo
J14 (50 mg/kg; intraperitoneal injection; daily; for 16 days; BALB/c nude female mice) treatment significantly reduces the average tumor volume. The masses and weights of the primary tumors excised from the J14-treated mice are significantly lower compared with those of the control mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Six-week-old BALB/c nude female mice injected with A549 cells [1] |
| Dosage: | 50 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 16 days |
| Result: | Significantly reduced the growth of human lung tumor without acute toxicity. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01820780 | Assistance Publique - Hôpitaux de Paris |
Heart Failure
|
June 10, 2013 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 125 mg/mL ( 241.76 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9341 mL | 9.6704 mL | 19.3409 mL |
| 5 mM | 0.3868 mL | 1.9341 mL | 3.8682 mL |
| 10 mM | 0.1934 mL | 0.9670 mL | 1.9341 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.17 mg/mL (4.20 mM); Clear solution